As for any degenerative disease, early diagnosis in prostate cancer is crucial to improve patients’ quality of life and reduce the mortality rate, which amounts to 350,000 deaths each year.
When prostate cancer is suspected, diagnosis must be confirmed by a biopsy and subsequent histological analysis. However, biopsy is far from being accurate, as its mostly manual nature causes a significant diagnostic error that may exceed 25%.
new cases
A single cart holding the robotic needle positioner and housing all the electronic components
The Robiopsy Project aims at evolving the robotic device for prostate cancer biopsy demonstrated during the ERC-PoC PROST into a product prototype that will be ready for clinical trials.
A multi-centric study will collect data for automatic prostate segmentation and lesion identification.
In parallel to the technical development, the project will analyse the business case of prostate biopsy in selected European Countries, and the time/cost reduction due to the new device.
Robiopsy EU Project has reached its conclusion after bringing together robotics, AI, clinical expertise and innovation management around a shared goal: improving the way prostate biopsy procedures can be planned…
The ROBIOPSY partners have successfully completed REGOLUS, the prototype developed within the ROBIOPSY project and funded by the European Innovation Council through an EIC Transition grant. REGOLUS is a semi-automatic,…
We are happy to announce that the Robiopsy project was presented during the 17th SIHTA Società Italiana Health Technology Assessment national congress, which took place from 5 to 7 November…
Colleagues from the University Hospital Freiburg represented Robiopsy at the annual congress of the European Association of Urology in Paris (EAU 2024) at the beginning of April. Among many other urological…
The company was founded by a group of researchers from
the University of Verona, leaded by Professor Paolo Fiorini and with an experience in the field of medical robotics of more than 15 years.
